Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.

Alexandr PoprachIgor KissMichal StanikTamara BarusovaLenka PospisilovaOndrej FialaJindrich KopeckyIgor RichterBohuslav MelicharHana StudentovaRadek LakomyMilos HolanekAneta RozsypalovaAnezka ZemankováMarek SvobodaTomas Buchler

Published in: Targeted oncology (2023)

In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.

Keyphrases

end stage renal disease
metastatic renal cell carcinoma
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported